Skip to content
Governance Register

← US public companies

Anacor Pharmaceuticals, Inc.

SEC CIK 1411158 · ANAC · last insider filing 2016-06-24

Directors (from insider filings)

NameCapacity as filedFilings
Leschly Mark Director filed 2010 - 2016
Rieflin William JL Director filed 2011 - 2016
Berns Paul L Director · President and CEO filed 2012 - 2016
Wierenga Wendall Director filed 2014 - 2016
Hove Anders D Director filed 2010 - 2016
Leonard Keith R Director filed 2014 - 2016
Shapiro Lucy Director filed 2010 - 2016
Klingenstein Paul H Director filed 2010 - 2014
Perry David P Director · President and CEO filed 2010 - 2014
Markham Richard J Director filed 2010 - 2011
Hong Zhi Director filed 2010 - 2010

Officers (from insider filings)

NameTitle as filedFilings
Ippolito Vincent P EVP & Chief Commercial Officer filed 2014 - 2016
Zane Lee VP, Clinical Dev & Interim CMO filed 2013 - 2016
Sullivan Ryan T Sr. VP and General Counsel filed 2014 - 2016
Bell Graeme Executive VP and CFO filed 2015 - 2016
Maples Kirk R Senior VP, Program Management filed 2010 - 2015
Plattner Jacob j Senior VP, Research filed 2010 - 2015
Rodriguez Carmen R Snr VP Reg Afrs & Qual. Assur. filed 2014 - 2015
Parker Geoffrey M. Sr. V.P. & CFO filed 2010 - 2015
Chanda Sanjay VP, Int. Head of Drug Dev. filed 2013 - 2015
Heyman Irwin A Senior VP, Drug Development filed 2010 - 2012

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.